Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...
Q1 2025 Management View CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors ...
Pharming Group excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow. Check out my recommendation for PHAR stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback